Viewing Study NCT00920868


Ignite Creation Date: 2025-12-24 @ 6:29 PM
Ignite Modification Date: 2025-12-25 @ 3:59 PM
Study NCT ID: NCT00920868
Status: COMPLETED
Last Update Posted: 2016-02-03
First Post: 2009-06-10
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: XAD - Xelox (Capecitabine + Oxaliplatin) + Bevacizumab + Dasatinib
Sponsor: Herbert Hurwitz, MD
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module